Immunotherapies, Novel Agents in Hepatocellular Carcinoma
This video examines the promise of recent trials studying single-agent immunotherapy as well as ongoing trials testing combinations of immune-checkpoint inhibition.
Anti–CTLA-4 and anti–PD-1 checkpoint inhibitors have both shown promise in the treatment of hepatocellular carcinoma (HCC).
In this video, Ghassan K. Abou-Alfa, MD, of Memorial Sloan Kettering Cancer Center in New York, discusses the promise of recent trials that have studied single-agent immunotherapy and ongoing trials testing combinations of immunotherapies and immune-checkpoint inhibition in different lines of treatment.
Abou-Alfa also highlights the latest results in second-line HCC treatment using the multikinase inhibitor regorafenib, and looks ahead at trials involving c-MET inhibition for patients with HCC.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
![“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F9b290688648a249e516474c175a3c06309426d15-2950x1568.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.")
